Testicular cancer incidence to rise by 25% by 2025 in Europe? Model-based predictions in 40 countries using population-based registry data
Introduction
Over 52,000 new cases of testicular cancer were estimated worldwide in 2008 [1]. The disease affects mainly White Caucasian populations, with rates in several of the highest-risk populations in Europe (Switzerland, Norway and Denmark) ten times those observed in most populations residing in Asia and Africa [2]. Within European countries, testicular cancer incidence rates vary sevenfold [3], and account for 1% of all male cancers. It is frequently the most common malignancy among young adult men (aged 15–34).
Attention was first drawn to rises in testicular cancer in England and Wales [4], and Denmark [5] half a century ago; numerous reports subsequently emerged detailing the rapid and general increases in incidence rates in adolescent men and young adults in many European countries over the last few decades [6], [7], [8], [9], [10] with testicular cancer trends mainly driven by birth cohort effects [8], [11], [12], [13]. Reasons for the distinct geographical and temporal variations in testicular cancer incidence are still however not well understood.
In light of the escalation in testicular cancer incidence in many populations and the high curability of the disease if adequate treatment regimens are adopted, we predict the future burden in 40 European countries for the year 2025 to support decision makers in resource allocation and planning for the optimal care of patients. Based on age-period-cohort models, we extrapolate the observed trends or make regional assumptions to quantify the future burden using, where possible, the high-quality data from population-based cancer registries across Europe. We highlight the increase in incidence rates and the number of future patients requiring care in terms of changes in risk versus changes in population ageing and growth. The results are discussed in the context of disease aetiology and the prospects for prevention and treatment of testicular cancer.
Section snippets
Data sources
We extracted the number of testicular cancer incidence (ICD10 C62) by year of diagnosis and 5-year age group from several sources. Firstly, data series from regional or national population-based cancer registries in Europe were extracted from Cancer Incidence in Five Continents (CI5) Volumes I to IX [2]. The specific requirement for the inclusion of a registry was at least fifteen consecutive years of data available alongside compilation in the latest Volume (IX) of the CI5 series. This
Results
The observed and predicted trends in the age-standardised incidence rates (ASR) of testicular cancer are presented in Fig. 1, for 23 European countries, and the rates circa 2005 and 2025 are compared in Fig. 2. While there is remarkable heterogeneity in the observed incidence rates between countries and regions, a general increase in rates in the range of 20–70% is predicted for most countries. The exceptions are predominantly in some Northern and Western European countries like in Denmark,
Discussion
We predict that by 2025, there will be almost 23,000 new cases of testicular cancer in Europe per year, a rise of almost 24% from the estimated 18,400 cases in 2005. Despite substantial heterogeneity in the rates of the disease in the recorded past and the predicted future, the vast majority of European countries will see an increasing burden over the next two decades. The predicted increase is seen in 20 of the 23 populations with recorded incidence data, estimated at over 20% over the two
Conflict of interest statement
None declared.
Acknowledgements
This work was developed at the International Agency for Research on Cancer (IARC, http://www.iarc.fr). No specific funding was received for this study. Ms Le Cornet is partially supported by a collaborative research agreement between IARC and Centre Léon Bérard (NORDTEST project). The authors gratefully acknowledged the following cancer registries who have contributed in sharing their data needed as baseline for incidence prediction: Austria – Austrian Cancer Registry(Mrs Zielonke); Landes
References (37)
- et al.
Cancer incidence and mortality patterns in Europe: estimates for 40 countries in 2012
Eur J Cancer
(2013) - et al.
Time trends in testicular cancer in Croatia 1983–2007: rapid increases in incidence, no declines in mortality
Cancer Epidemiol
(2012) - et al.
Global cancer transitions according to the Human Development Index (2008–2030): a population-based study
Lancet Oncol
(2012) - et al.
Testicular germ cell cancer incidence in an immigration perspective, Denmark, 1978 to 2003
J Urol
(2010) - Ferlay J, Shin H, Bray F, Forman D, Mathers C, Parkin D. GLOBOCAN 2008 v2.0, Cancer incidence and mortality worldwide....
- Ferlay J, Parkin D, Curado M, et al. cancer incidence in five continents, vols. I to IX. IARC Cancer Base No. 9. IARC...
- et al.
Trends in mortality from neoplasms of the testis
Cancer
(1958) A doubling of morbidity from testis carcinoma in Copenhagen, 1943–1962
Acta Pathol Microbiol Scand
(1968)- et al.
International trends in the incidence of testicular cancer, 1973–2002
Cancer Epidemiol Biomarkers Prev
(2010) - et al.
Testicular cancer
Cancer Surv
(1994)
Testicular cancer incidence in eight northern European countries: secular and recent trends
Cancer Epidemiol Biomarkers Prev
Thirty year trends in testicular cancer mortality in Europe: gaps persist between the East and West
Acta Oncol
International variations and trends in testicular cancer incidence and mortality
Eur Urol
Trends in testicular cancer incidence and mortality in 22 European countries: continuing increases in incidence and declines in mortality
Int J Cancer
Testicular cancer: marked birth cohort effects on incidence and a decline in mortality in southern Netherlands since 1970
Int J Cancer
Markedly increased incidence and improved survival of testicular cancer in the Netherlands
Acta Oncol
Cited by (128)
Epidemiology, Management, and Survival Outcomes of Germ Cell Cancer in Southern Portugal: A Population-Based Study (2008-2012)
2024, Clinical Genitourinary CancerpiR-36249 and DHX36 together inhibit testicular cancer cells progression by upregulating OAS2
2023, Non-coding RNA ResearchFrench AFU Cancer Committee Guidelines - Update 2022-2024: testicular germ cell cancer
2022, Progres en UrologieActivation of estrogen receptor ESR1 and ESR2 induces proliferation of the human testicular embryonal carcinoma NT2/D1 cells
2022, Molecular and Cellular EndocrinologyEndocrine-disrupting chemicals affect Sertoli TM4 cell functionality through dysregulation of gap junctional intercellular communication in vitro
2022, Food and Chemical ToxicologyCitation Excerpt :Testicular cancer causes approximately 75,000 cases and 9,500 deaths per year (IARC, 2021). Its incidence alarmingly rises yearly, doubled in the last 20–40 years with marked geographic and racial variation (Le Cornet et al., 2014; Vega et al., 2012; Walschaerts et al., 2008; Znaor et al., 2020). Testicular tumors are the most common malignancy among men of reproductive age, accounting for up to 60% of all tumors and the major cause of their death (Peng et al., 2009).